Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate

BACKGROUND: Among patients with schizophrenia, nonadherence to oral atypical antipsychotics (OAAs) leads to increased risk of relapses, which entails substantial economic burden. OBJECTIVE: To evaluate the impact on health care costs and relapse rates of switching patients with schizophrenia from OA...

Descripción completa

Detalles Bibliográficos
Autores principales: Morrison, Laura, Lin, Dee, Benson, Carmela, Ghelerter, Isabelle, Vermette-Laforme, Maude, Lefebvre, Patrick, Pilon, Dominic
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394189/
https://www.ncbi.nlm.nih.gov/pubmed/36354209
http://dx.doi.org/10.18553/jmcp.2022.22215

Ejemplares similares

Ejemplares similares